Clinical trials of a nasal spray developed by Israel. SaNOtize is shown to significantly reduce viral load and shorten the course of COVID-19
A report in The Lancet, the world’s most respected medical journal, concludes that their nitric oxide nasal spray (NONS), used six times a day for seven days, was “effective in accelerating the reduction of SARS-CoV-2 RNA of the nasal cavity.
The spray reduces viral load, the amount of virus in the body, by about 94% in 24 hours, if used within three days of a positive COVID-19 test. That number jumps to 99% within 48 hours in participants at highest risk of disease progression.
The study was conducted at 20 clinical centers in India and evaluated 306 participants who had mild symptoms of COVID-19, of whom approximately 46% were vaccinated.
It occurred during the delta and omicron surges, suggesting that the treatment may be effective against those variants.
“The results of the Phase 3 study strongly support the safety and efficacy of NONS in treating COVID-19 and its known variants,” said Gilly Regev, PhD, Co-Founder and CEO of SaNOtize.
“Nitric oxide blocks entry into the cells of the nasal passage, killing the virus and stopping its replication, which is why the viral load is reduced so quickly with NONS. Viral load has been linked to infectivity, poorer health outcomes, and complications of prolonged COVID.
“There is growing evidence that NONS represents an effective and well-tolerated antiviral treatment that significantly shortens the course of COVID-19.”
SaNOtize, founded in 2017 by Dr. Gilly Regev and Dr. Chris Miller, and now based in Vancouver, Canada, has developed a proprietary platform technology that enables topical delivery of nitric oxide to treat a variety of bacteria, fungi and viruses. diseases.